临床药理学中的有效半衰期。 - Suppr | 超能文献

相似文献

1

Effective half-life in clinical pharmacology.临床药理学中的有效半衰期。

J Clin Pharmacol. 1995 Aug;35(8):763-6. doi: 10.1002/j.1552-4604.1995.tb04117.x.

2

Inhibition of human aldose and aldehyde reductases by non-steroidal anti-inflammatory drugs.非甾体抗炎药对人醛糖还原酶和醛还原酶的抑制作用。

Adv Exp Med Biol. 1999;463:493-9. doi: 10.1007/978-1-4615-4735-8_62.

3

The molecular basis for inhibition of sulindac and its metabolites towards human aldose reductase.舒林酸及其代谢物抑制人醛糖还原酶的分子基础。

FEBS Lett. 2012 Jan 2;586(1):55-9. doi: 10.1016/j.febslet.2011.11.023. Epub 2011 Dec 8.

4

Pharmacokinetics of the aldose reductase inhibitor tolrestat: studies in healthy young and elderly male and female subjects and in subjects with diabetes.

Clin Pharmacol Ther. 1996 Jun;59(6):603-12. doi: 10.1016/S0009-9236(96)90000-4.

5

Structural analysis of sulindac as an inhibitor of aldose reductase and AKR1B10.舒林酸作为醛糖还原酶和AKR1B10抑制剂的结构分析

Chem Biol Interact. 2015 Jun 5;234:290-6. doi: 10.1016/j.cbi.2014.12.018. Epub 2014 Dec 20.

6

Pharmacodynamics and pharmacokinetics of topical adapalene.外用阿达帕林的药效学与药代动力学。

J Am Acad Dermatol. 1998 Aug;39(2 Pt 3):S17-24. doi: 10.1016/s0190-9622(98)70440-2.

7

An old NSAID revisited: crystal structure of aldose reductase in complex with sulindac at 1.0 Å supports a novel mechanism for its anticancer and antiproliferative effects.一种旧的非甾体抗炎药的新发现：醛糖还原酶与舒林酸复合物在1.0 Å分辨率下的晶体结构支持其抗癌和抗增殖作用的新机制。

ChemMedChem. 2011 Dec 9;6(12):2155-7. doi: 10.1002/cmdc.201100374. Epub 2011 Oct 13.

8

Efficacy and safety of nonsteroidal anti-inflammatory drugs in the therapy of diabetic neuropathy.非甾体抗炎药治疗糖尿病性神经病变的疗效与安全性

Arch Intern Med. 1987 Aug;147(8):1442-4.

9

Absorption of sulindac from a novel (Pro-SorbTM) liquid formulation.

Biopharm Drug Dispos. 1996 Apr;17(3):209-21. doi: 10.1002/(SICI)1099-081X(199604)17:3<209::AID-BDD956>3.0.CO;2-6.

10

Pharmacokinetics and dialyzability of sulindac and metabolites in patients with end-stage renal failure.终末期肾衰竭患者中舒林酸及其代谢产物的药代动力学和可透析性

J Clin Pharmacol. 1993 Jun;33(6):527-34. doi: 10.1002/j.1552-4604.1993.tb04699.x.

引用本文的文献

1

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria.培格西他单抗在阵发性睡眠性血红蛋白尿症患者中的群体药代动力学及药代动力学/药效学分析。

Drugs R D. 2024 Dec;24(4):563-573. doi: 10.1007/s40268-024-00500-7. Epub 2024 Nov 29.

2

Evaluation of Effective Half-Life and Its Impact on Time to Steady State for Oral MeltDose Tacrolimus (LCPT) in De Novo Kidney Transplant Recipients.对初发肾移植受者口服溶融剂型他克莫司（LCPT）的有效半衰期及其对达到稳态时间的影响进行评估。

Ther Drug Monit. 2025 Feb 1;47(1):169-173. doi: 10.1097/FTD.0000000000001270. Epub 2024 Oct 24.

3